Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer.
By S. Braun, K. Pantel, P. Müller, W. Janni, F. Hepp, C. Kentenich, Stephan Gastroph, Artur Wischnik, Thomas Dimpfl, G. Kindermann and 2 more. New England Journal of Medicine, 2000
961 citations recorded by the source corpus.
Subfields: Emergency Medicine, Hematology, Oncology
View Paper: https://www.semanticscholar.org/paper/10a2fd091c387932729647c19384a66d179453cb
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hematology
In Oncology
Citations in the corpus
- American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. (2007, background): “The picture is complicated further by the fact that 1% to 2% of normal volunteers will demonstrate epithelial cells in the marrow by all of these techniques.(273,274) This observation raises the question of whether individuals without cancer have epithelial cells Harris et al”
- Metastasis: from dissemination to organ-specific colonization (2009, background): “Malignant cells from breast tumours that disseminate early can reside as single cells or as micrometastatic clusters, as shown in studies of bone marrow samples from patients without overt metastatic diseas”
- Cancer to bone: a fatal attraction (2011, neutral): “Evidence exists that DTCs can persist in the bone marrow for years in a quiescent state, and are resistant to cancer therapie”
- PGC-1α mediates mitochondrial biogenesis and oxidative phosphorylation to promote metastasis (2014, neutral): “Detection of disseminated tumor cells in bone marrow was performed with anticytokeratin monoclonal antibody A45-B/B3 as previously described(42) and according to international standards(43).”